Silence Therapeutics (SLN) and Its Peers Head to Head Analysis

Silence Therapeutics (NASDAQ:SLN – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Silence Therapeutics to similar businesses based on the strength of its dividends, valuation, risk, profitability, earnings, analyst recommendations and institutional ownership.

Profitability

This table compares Silence Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Silence Therapeutics -8,943.86% -56.32% -32.42%
Silence Therapeutics Competitors -12,519.20% -215.47% -31.42%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Silence Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silence Therapeutics 1 4 2 0 2.14
Silence Therapeutics Competitors 9959 15361 45766 1602 2.54

Silence Therapeutics currently has a consensus target price of $24.00, suggesting a potential upside of 21.15%. As a group, “Biotechnology” companies have a potential upside of 114.84%. Given Silence Therapeutics’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Silence Therapeutics has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Silence Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Silence Therapeutics’ rivals have a beta of -1.85, indicating that their average stock price is 285% less volatile than the S&P 500.

Earnings and Valuation

This table compares Silence Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Silence Therapeutics $560,000.00 -$88.61 million -18.51
Silence Therapeutics Competitors $704.12 million $8.07 million -17.98

Silence Therapeutics’ rivals have higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Silence Therapeutics rivals beat Silence Therapeutics on 9 of the 13 factors compared.

About Silence Therapeutics

(Get Free Report)

Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company’s research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders.

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.